A 74-year-old man with Parkinson's disease, orthostatic hypotension, type 2 diabetes, and benign prostatic hyperplasia is taking levodopa/carbidopa 25/100 three times daily, pramipexole 1.05mg three times daily, metformin 500mg twice daily, tamsulosin 400mcg once daily, finasteride 5mg once daily, and bisoprolol 2.5mg once daily prescribed by cardiology for palpitations. He reports increasing frequency of falls, particularly when standing. Which medication is most appropriate to discontinue to reduce his fall risk?
Q32
A 67-year-old woman with multimorbidity including type 2 diabetes, heart failure (NYHA class II), and severe osteoarthritis is reviewed. She takes 12 regular medications. She expresses feeling overwhelmed by her medication regimen and reports 'tablet fatigue'. According to the principles of realistic medicine and patient-centred care in multimorbidity management, what is the most appropriate initial approach?
Q33
A 70-year-old man with type 2 diabetes, hypertension, stage 3b CKD (eGFR 38 ml/min/1.73m²), and gout takes multiple medications including metformin 500mg twice daily, sitagliptin 50mg once daily, ramipril 10mg once daily, amlodipine 10mg once daily, atorvastatin 80mg once daily, allopurinol 100mg once daily, and aspirin 75mg once daily. His recent blood tests show: HbA1c 52 mmol/mol, uric acid 420 µmol/L, potassium 5.2 mmol/L. He has had two acute gout attacks in the past 6 months. What is the most appropriate adjustment to optimise his gout management?
Q34
During a comprehensive medication review for a 72-year-old man with COPD (post-bronchodilator FEV1 45% predicted), ischaemic heart disease, and anxiety, you note he is taking salbutamol inhaler as required, tiotropium 18mcg once daily, fluticasone/salmeterol 500/50 twice daily, bisoprolol 5mg once daily, aspirin 75mg once daily, atorvastatin 80mg once daily, and diazepam 5mg twice daily for 2 years. Which medication poses the greatest concern for long-term use in this patient?
Q35
A 75-year-old woman with heart failure (LVEF 35%), atrial fibrillation, type 2 diabetes, and chronic pain from lumbar spinal stenosis attends for medication review. She takes bisoprolol, ramipril, furosemide, apixaban, metformin, atorvastatin, lansoprazole, and co-codamol 30/500 four times daily for the past 18 months. She reports chronic constipation requiring regular laxatives and occasional confusion noticed by her daughter. What is the most appropriate action regarding her analgesic management?
Q36
According to the 2015 STOPP/START criteria, which of the following represents a STOPP criterion (potentially inappropriate medication) in older adults?
Q37
A 68-year-old man attends for his annual chronic disease review. He has type 2 diabetes, hypertension, stage 3a CKD (eGFR 52 ml/min/1.73m²), and gout. His current medications are metformin 1g twice daily, gliclazide 160mg twice daily, allopurinol 300mg once daily, ramipril 10mg once daily, and amlodipine 10mg once daily. His blood pressure is 142/88 mmHg and HbA1c is 64 mmol/mol (8%). He reports two episodes of nocturnal hypoglycaemia in the past month. What is the most appropriate adjustment to his medication regimen?
Q38
A 73-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and recurrent falls is taking methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg twice daily, prednisolone 5mg once daily, alendronic acid 70mg weekly, calcium/vitamin D supplements, ramipril 5mg once daily, and bendroflumethiazide 2.5mg once daily. She has had three falls in the past 6 months with no clear mechanical cause. Which medication is most important to review and potentially discontinue to reduce fall risk?
Q39
During a medication review for a 77-year-old man with atrial fibrillation, heart failure (NYHA class II), type 2 diabetes, and benign prostatic hyperplasia, you note he is taking apixaban 5mg twice daily, bisoprolol 2.5mg once daily, furosemide 40mg once daily, metformin 500mg twice daily, tamsulosin 400mcg once daily, and finasteride 5mg once daily. His most recent blood results show: eGFR 42 ml/min/1.73m², HbA1c 58 mmol/mol, potassium 5.8 mmol/L. What is the most appropriate immediate action?
Q40
A 69-year-old woman with heart failure (LVEF 40%), type 2 diabetes, hypertension, and depression takes 11 regular medications. During a structured medication review, she reports a dry cough that has persisted for 6 months. Her medications include ramipril 10mg once daily, bisoprolol 5mg once daily, furosemide 40mg once daily, atorvastatin 80mg once daily, aspirin 75mg once daily, metformin 1g twice daily, gliclazide 80mg twice daily, amlodipine 5mg once daily, sertraline 100mg once daily, lansoprazole 30mg once daily, and calcium/vitamin D supplements. What is the most appropriate initial management?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 31: A 74-year-old man with Parkinson's disease, orthostatic hypotension, type 2 diabetes, and benign prostatic hyperplasia is taking levodopa/carbidopa 25/100 three times daily, pramipexole 1.05mg three times daily, metformin 500mg twice daily, tamsulosin 400mcg once daily, finasteride 5mg once daily, and bisoprolol 2.5mg once daily prescribed by cardiology for palpitations. He reports increasing frequency of falls, particularly when standing. Which medication is most appropriate to discontinue to reduce his fall risk?
A. Pramipexole due to dopamine agonist-associated impulse control disorders
B. Tamsulosin due to alpha-blocker effects on blood pressure
C. Bisoprolol due to effects on heart rate response to postural changes (Correct Answer)
D. Finasteride due to effects on muscle strength
E. Metformin due to risk of lactic acidosis
Explanation: ***Bisoprolol due to effects on heart rate response to postural changes***
- **Bisoprolol** is a beta-blocker that inhibits the normal **compensatory tachycardia** necessary to maintain blood pressure when standing, significantly worsening **orthostatic hypotension** in a patient already predisposed.
- Given the patient's existing **Parkinson's disease** and history of falls, removing a drug that blunts the autonomic response to postural changes is a priority for reducing fall risk.
*Pramipexole due to dopamine agonist-associated impulse control disorders*
- While **dopamine agonists** like pramipexole can cause or worsen **orthostatic hypotension**, the reason for discontinuation specified here is **impulse control disorders**, which is not the direct cause of his falls when standing.
- Abruptly stopping or significantly reducing Parkinson's medications can lead to severe **motor deterioration** and should be carefully considered, especially when other more direct contributors to falls exist.
*Tamsulosin due to alpha-blocker effects on blood pressure*
- **Tamsulosin** is a selective **alpha-1A blocker** primarily targeting the prostate, which typically has a much lower risk of causing significant systemic **hypotension** or exacerbating orthostatic hypotension compared to non-selective alpha-blockers.
- Although all alpha-blockers can potentially contribute to orthostatic changes, bisoprolol has a more direct and substantial impact on the cardiovascular compensatory mechanisms essential for standing blood pressure maintenance.
*Finasteride due to effects on muscle strength*
- **Finasteride** is a 5-alpha-reductase inhibitor used for benign prostatic hyperplasia and does not have clinically significant effects on **skeletal muscle strength**, directly contribute to **orthostatic hypotension**, or increase fall risk.
- Its mechanism of action is focused on hormonal modulation within the prostate, unrelated to neuromuscular function or cardiovascular stability.
*Metformin due to risk of lactic acidosis*
- **Metformin** is an oral hypoglycemic agent used for **type 2 diabetes** and is not associated with directly causing **orthostatic hypotension** or increasing the risk of falls due to its mechanism of action.
- While **lactic acidosis** is a potential serious side effect, it is unrelated to the patient's primary complaint of falls specifically when standing, which points to orthostatic dysregulation.
Question 32: A 67-year-old woman with multimorbidity including type 2 diabetes, heart failure (NYHA class II), and severe osteoarthritis is reviewed. She takes 12 regular medications. She expresses feeling overwhelmed by her medication regimen and reports 'tablet fatigue'. According to the principles of realistic medicine and patient-centred care in multimorbidity management, what is the most appropriate initial approach?
A. Explore the patient's priorities, concerns, and what matters most to her regarding her conditions and treatments (Correct Answer)
B. Explain that all medications are necessary and provide detailed written instructions
C. Simplify the regimen by stopping the least important medications immediately
D. Refer to a specialist multimorbidity clinic for complex case management
E. Arrange for a compliance aid to improve medication adherence
Explanation: ***Explore the patient's priorities, concerns, and what matters most to her regarding her conditions and treatments***
- This approach is fundamental to **patient-centred care** and **realistic medicine**, directly addressing the patient's reported 'tablet fatigue' and feeling overwhelmed by eliciting her **perspectives and values**.
- Understanding the patient's **priorities, treatment burden**, and what truly **matters to her** enables a **shared decision-making** process for optimizing her complex medication regimen.
*Explain that all medications are necessary and provide detailed written instructions*
- This is a **paternalistic approach** that ignores the patient's expressed **'tablet fatigue'** and high **treatment burden**, failing to acknowledge her distress.
- Simply reinforcing the necessity of all medications without a review or patient input disregards the principles of **shared decision-making** and may worsen adherence and satisfaction.
*Simplify the regimen by stopping the least important medications immediately*
- While **deprescribing** is often appropriate in multimorbidity, doing so **immediately** and unilaterally without patient discussion or a thorough assessment of each medication's **benefit-harm ratio** is premature and potentially unsafe.
- Determining which medications are 'least important' should be a collaborative process, considering the patient's **goals** and the potential for **adverse withdrawal effects**.
*Refer to a specialist multimorbidity clinic for complex case management*
- Although specialist input might eventually be beneficial, the **initial step** in managing multimorbidity in primary care is to engage directly with the patient to understand their **concerns and goals**.
- Referral without this foundational patient-centred conversation bypasses the primary clinician's role in establishing a **therapeutic relationship** and addressing immediate patient distress.
*Arrange for a compliance aid to improve medication adherence*
- A **compliance aid** (e.g., pillbox) helps with the practical organization of medications but does not address the underlying **'tablet fatigue'** or the sheer **number of medications** the patient feels overwhelmed by.
- This solution focuses solely on **adherence** without first exploring if the current medication burden is appropriate or aligned with the patient's overall **quality of life** and preferences.
Question 33: A 70-year-old man with type 2 diabetes, hypertension, stage 3b CKD (eGFR 38 ml/min/1.73m²), and gout takes multiple medications including metformin 500mg twice daily, sitagliptin 50mg once daily, ramipril 10mg once daily, amlodipine 10mg once daily, atorvastatin 80mg once daily, allopurinol 100mg once daily, and aspirin 75mg once daily. His recent blood tests show: HbA1c 52 mmol/mol, uric acid 420 µmol/L, potassium 5.2 mmol/L. He has had two acute gout attacks in the past 6 months. What is the most appropriate adjustment to optimise his gout management?
A. Add colchicine 500mcg twice daily for prophylaxis during dose adjustment
B. Stop allopurinol and switch to febuxostat 80mg once daily
C. Increase allopurinol to 200-300mg once daily with careful monitoring (Correct Answer)
D. Add benzbromarone 50mg once daily to enhance uric acid excretion
E. Continue current allopurinol dose and add prednisolone 5mg daily
Explanation: ***Increase allopurinol to 200-300mg once daily with careful monitoring***
- The patient's **serum uric acid (420 µmol/L)** is above the target of <360 µmol/L (or <300 µmol/L for recurrent gout), and the current 100mg dose is insufficient despite **CKD stage 3b**.
- Modern guidelines emphasize a "treat-to-target" approach where **allopurinol** is uptitrated gradually, even in renal impairment, with close monitoring for toxicity and gradual dose increments to achieve the target uric acid.
*Add colchicine 500mcg twice daily for prophylaxis during dose adjustment*
- While **prophylactic colchicine** is recommended when initiating or increasing urate-lowering therapy to prevent flares, it does not address the underlying persistent **hyperuricaemia**.
- In this patient with an **eGFR 38 ml/min/1.73m²**, the dose of colchicine would likely need to be reduced (e.g., 500mcg once daily) to avoid toxicity.
*Stop allopurinol and switch to febuxostat 80mg once daily*
- **Febuxostat** is typically reserved for patients who are intolerant to allopurinol, where allopurinol is contraindicated, or when it's ineffective at maximum doses, none of which apply here.
- It carries specific **cardiovascular cautions** in certain patient populations and is not the first-line adjustment when allopurinol has not yet been optimized.
*Add benzbromarone 50mg once daily to enhance uric acid excretion*
- **Benzbromarone** is a uricosuric agent and is generally less effective in patients with an **eGFR below 30-50 ml/min**, making it unsuitable for this patient's CKD stage 3b.
- It is not a standard first-line addition and is typically only available via **specialist secondary care** channels in many regions.
*Continue current allopurinol dose and add prednisolone 5mg daily*
- **Long-term corticosteroids** are not an appropriate management strategy for chronic gout due to significant side effects that would worsen the patient's **hypertension and diabetes**.
- This approach fails to address the persistent **hyperuricaemia**, which is the root cause of the patient's frequent gout attacks and requires effective urate-lowering therapy.
Question 34: During a comprehensive medication review for a 72-year-old man with COPD (post-bronchodilator FEV1 45% predicted), ischaemic heart disease, and anxiety, you note he is taking salbutamol inhaler as required, tiotropium 18mcg once daily, fluticasone/salmeterol 500/50 twice daily, bisoprolol 5mg once daily, aspirin 75mg once daily, atorvastatin 80mg once daily, and diazepam 5mg twice daily for 2 years. Which medication poses the greatest concern for long-term use in this patient?
A. Bisoprolol due to risk of bronchospasm in COPD
B. Fluticasone/salmeterol due to increased pneumonia risk
C. Diazepam due to risk of dependence, falls, and cognitive impairment (Correct Answer)
D. Atorvastatin due to interaction with inhaled corticosteroids
E. Tiotropium due to cardiovascular effects in ischaemic heart disease
Explanation: ***Diazepam due to risk of dependence, falls, and cognitive impairment***
- Long-term use of **benzodiazepines** (over 4 weeks) is strongly discouraged in the elderly due to elevated risks of **cognitive impairment**, **falls**, and **respiratory depression**, especially in a patient with **COPD**.
- The **STOPP criteria** specifically categorize long-term benzodiazepine use as potentially inappropriate medications (PIMs) in older adults to prevent adverse drug events.
*Bisoprolol due to risk of bronchospasm in COPD*
- **Cardioselective beta-blockers** like **bisoprolol** are generally safe in COPD patients and are strongly indicated here for the management of **ischaemic heart disease**.
- Recent evidence suggests they do not significantly increase **bronchoconstriction** or reduce the efficacy of bronchodilators in the majority of COPD cases.
*Fluticasone/salmeterol due to increased pneumonia risk*
- While **Inhaled Corticosteroids (ICS)** are associated with an increased risk of **pneumonia** in COPD patients, they are still indicated when there is a risk of frequent exacerbations.
- Although a concern, it is considered a manageable risk compared to the acute dangers associated with long-term **high-dose benzodiazepine** use in this age group.
*Atorvastatin due to interaction with inhaled corticosteroids*
- There is no clinically significant **pharmacokinetic interaction** between **atorvastatin** and **inhaled corticosteroids** such as fluticasone.
- Atorvastatin is essential for **secondary prevention** in this patient given their history of **ischaemic heart disease**.
*Tiotropium due to cardiovascular effects in ischaemic heart disease*
- Long-acting muscarinic antagonists (**LAMAs**) like **tiotropium** have been proven safe in large trials for patients with co-existing **cardiovascular disease**.
- It provides vital maintenance therapy for **COPD symptom control** and has not been linked to increased mortality in patients with heart disease.
Question 35: A 75-year-old woman with heart failure (LVEF 35%), atrial fibrillation, type 2 diabetes, and chronic pain from lumbar spinal stenosis attends for medication review. She takes bisoprolol, ramipril, furosemide, apixaban, metformin, atorvastatin, lansoprazole, and co-codamol 30/500 four times daily for the past 18 months. She reports chronic constipation requiring regular laxatives and occasional confusion noticed by her daughter. What is the most appropriate action regarding her analgesic management?
A. Continue co-codamol and add docusate regularly to manage constipation
B. Switch to tramadol 50mg four times daily for better pain control
C. Review pain management strategy and consider switching to paracetamol with topical NSAIDs (Correct Answer)
D. Add amitriptyline 10mg at night for neuropathic pain component
E. Increase co-codamol to 60/1000 for improved analgesia
Explanation: ***Review pain management strategy and consider switching to paracetamol with topical NSAIDs***
- Long-term **opioid use** (codeine in co-codamol) is likely contributing to the patient's **chronic constipation** and **confusion**, necessitating a reduction in opioid burden.
- Switching to **paracetamol** and **topical NSAIDs** provides safer analgesia with a lower risk of systemic side effects like gastrointestinal bleeding or worsening **heart failure** compared to oral NSAIDs.
*Continue co-codamol and add docusate regularly to manage constipation*
- This approach fails to address the likely cause of the patient's **confusion** and potential **falls risk** associated with chronic opioid use.
- It leads to **polypharmacy**, where a new medication is added solely to treat a side effect of an existing, potentially inappropriate medication.
*Switch to tramadol 50mg four times daily for better pain control*
- **Tramadol** is another opioid and would likely exacerbate the patient’s **constipation** and **confusion** due to its central nervous system effects.
- It carries a risk of **serotonin syndrome** and lowered seizure threshold, especially in elderly patients with multiple comorbidities.
*Add amitriptyline 10mg at night for neuropathic pain component*
- Amitriptyline has strong **anticholinergic properties** that can worsen **confusion** and increase the risk of **urinary retention** and falls in the elderly.
- It is listed in the **Beers Criteria** as potentially inappropriate for older adults, particularly those with existing cognitive impairment.
*Increase co-codamol to 60/1000 for improved analgesia*
- Increasing the dose would further worsen **opioid-induced constipation** and increase the severity of **confusion** and sedation.
- High-dose opioids in a 75-year-old patient significantly increase the risk of **respiratory depression** and adverse cardiovascular events.
Question 36: According to the 2015 STOPP/START criteria, which of the following represents a STOPP criterion (potentially inappropriate medication) in older adults?
A. Absence of calcium and vitamin D supplementation in patients taking long-term corticosteroids
B. Use of proton pump inhibitors for uncomplicated peptic ulcer disease at full therapeutic dosage for more than 8 weeks (Correct Answer)
C. Absence of ACE inhibitor in systolic heart failure with reduced ejection fraction
D. Absence of antiplatelet therapy in patients with documented coronary artery disease
E. Use of aspirin and clopidogrel combination beyond 12 months after acute coronary syndrome
Explanation: ***Use of proton pump inhibitors for uncomplicated peptic ulcer disease at full therapeutic dosage for more than 8 weeks***
- This is a recognized **STOPP criterion** because prolonged **full-dose PPI** therapy for uncomplicated ulcers increases risks of **C. difficile infection**, **fractures**, and **hypomagnesemia**.
- Uncomplicated peptic ulcers typically heal within 8 weeks, making continued full-dose PPI use beyond this period potentially **inappropriate** without clear indication.
*Absence of calcium and vitamin D supplementation in patients taking long-term corticosteroids*
- This is a **START criterion**, identifying a potential **prescribing omission** rather than an inappropriate medication to stop.
- It highlights the importance of **osteoporosis prophylaxis** in older patients receiving systemic **corticosteroid therapy** to prevent fractures.
*Absence of ACE inhibitor in systolic heart failure with reduced ejection fraction*
- This represents a **START criterion** because **ACE inhibitors** are evidence-based treatments that improve survival and reduce hospitalizations in older adults with **systolic heart failure**.
- Failure to prescribe these agents when indicated is considered a **potential prescribing omission** (PPO) in geriatric care for cardiovascular health.
*Absence of antiplatelet therapy in patients with documented coronary artery disease*
- This is another **START criterion** aimed at ensuring secondary prevention for patients with established **vascular disease**.
- The criteria advocate for the **initiation** of antiplatelets to reduce the risk of future **myocardial infarction** and stroke.
*Use of aspirin and clopidogrel combination beyond 12 months after acute coronary syndrome*
- While long-term **dual antiplatelet therapy (DAPT)** increases bleeding risk, the 2015 STOPP/START criteria do not explicitly list this as a universal STOPP criterion in the same category as prolonged PPI use.
- The duration of DAPT is often individualized based on factors like **stent type** and **ischemic risk** versus bleeding risk, rather than a strict mandate for discontinuation at 12 months for all patients.
Question 37: A 68-year-old man attends for his annual chronic disease review. He has type 2 diabetes, hypertension, stage 3a CKD (eGFR 52 ml/min/1.73m²), and gout. His current medications are metformin 1g twice daily, gliclazide 160mg twice daily, allopurinol 300mg once daily, ramipril 10mg once daily, and amlodipine 10mg once daily. His blood pressure is 142/88 mmHg and HbA1c is 64 mmol/mol (8%). He reports two episodes of nocturnal hypoglycaemia in the past month. What is the most appropriate adjustment to his medication regimen?
A. Add dapagliflozin 10mg once daily to improve glycaemic control
B. Reduce gliclazide to 80mg twice daily and monitor blood glucose (Correct Answer)
C. Switch from metformin to sitagliptin due to chronic kidney disease
D. Increase ramipril to 20mg once daily to improve blood pressure control
E. Add spironolactone 25mg once daily for resistant hypertension
Explanation: ***Reduce gliclazide to 80mg twice daily and monitor blood glucose***
- The patient is experiencing recurrent **nocturnal hypoglycaemia**, which is a high-priority safety concern; **sulfonylureas** like gliclazide are the most common cause of this in type 2 diabetes.
- In an older patient with **multimorbidity** and an eGFR of 52, glycaemic targets should be individualized to avoid **over-treatment** and minimize the risk of dangerous hypoglycaemic events.
*Add dapagliflozin 10mg once daily to improve glycaemic control*
- While **SGLT2 inhibitors** have benefits in **CKD** and diabetes, adding a new glucose-lowering agent does not address the immediate danger of existing **hypoglycaemia**.
- The primary clinical focus must be the discontinuation or reduction of the offending agent before intensifying the regimen further.
*Switch from metformin to sitagliptin due to chronic kidney disease*
- **Metformin** is safe to continue at full dose as long as the **eGFR** is above 45 ml/min/1.73m² and only requires dose reduction once it falls below 45.
- **Sitagliptin** would not be a priority switch here as metformin remains first-line and is not the likely cause of the patient's **nocturnal hypoglycaemia**.
*Increase ramipril to 20mg once daily to improve blood pressure control*
- The current blood pressure of 142/88 mmHg is close to the standard target of **<140/90 mmHg**, and **10mg ramipril** is already the maximum licensed dose for hypertension.
- Increasing the ACE inhibitor beyond maximum recommended doses increases the risk of **hyperkalaemia** and renal dysfunction in patients with **Stage 3 CKD**.
*Add spironolactone 25mg once daily for resistant hypertension*
- The patient does not meet the criteria for **resistant hypertension**, as his blood pressure is nearly controlled on two agents, and he is not yet on a diuretic.
- **Spironolactone** carries a significant risk of **hyperkalaemia** in patients with CKD and should not be started without confirming potassium levels and maximizing first-line therapies.
Question 38: A 73-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and recurrent falls is taking methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg twice daily, prednisolone 5mg once daily, alendronic acid 70mg weekly, calcium/vitamin D supplements, ramipril 5mg once daily, and bendroflumethiazide 2.5mg once daily. She has had three falls in the past 6 months with no clear mechanical cause. Which medication is most important to review and potentially discontinue to reduce fall risk?
A. Hydroxychloroquine due to potential visual disturbances
B. Prednisolone due to its effects on bone density and muscle weakness
C. Bendroflumethiazide due to risk of postural hypotension and electrolyte disturbance (Correct Answer)
D. Alendronic acid due to risk of oesophageal irritation
E. Ramipril due to risk of hypotension
Explanation: ***Bendroflumethiazide due to risk of postural hypotension and electrolyte disturbance***- Thiazide diuretics are a major risk factor for falls in the elderly as they cause **postural hypotension**, **hyponatremia**, and **hypokalemia**, which interfere with stability.- They also increase **urinary urgency**, leading to rushed movements (nocturia/urgency) that frequently result in accidents in patients with existing mobility issues.*Prednisolone due to its effects on bone density and muscle weakness*- While long-term steroids cause **proximal myopathy** and **osteoporosis**, this patient's 5mg dose is relatively low and essential for controlling her **rheumatoid arthritis**.- Abruptly stopping steroids is dangerous due to **adrenal insufficiency** risk, and it is less likely to be the trigger for immediate, unexplained falls compared to diuretics.*Hydroxychloroquine due to potential visual disturbances*- Hydroxychloroquine can cause **retinopathy**, but visual changes typically develop very slowly over many years and do not present as sudden, frequent falls.- It is not associated with **orthostatic hypotension** or acute neurological symptoms that would predispose a patient to stumbling.*Alendronic acid due to risk of oesophageal irritation*- Alendronic acid is used to treat **osteoporosis** and actually helps prevent fractures if a fall occurs; it does not impair **balance or gait**.- Its primary side effects are **gastrointestinal**, such as esophagitis, which are unrelated to the mechanisms causing recurrent mechanical falls.*Ramipril due to risk of hypotension*- Although ACE inhibitors like ramipril can cause **hypotension**, they are statistically less likely than **thiazide diuretics** to cause the syncopal episodes or electrolyte shifts associated with falls.- Ramipril is often continued for its **cardioprotective and renoprotective** benefits unless symptomatic hypotension is clearly documented.
Question 39: During a medication review for a 77-year-old man with atrial fibrillation, heart failure (NYHA class II), type 2 diabetes, and benign prostatic hyperplasia, you note he is taking apixaban 5mg twice daily, bisoprolol 2.5mg once daily, furosemide 40mg once daily, metformin 500mg twice daily, tamsulosin 400mcg once daily, and finasteride 5mg once daily. His most recent blood results show: eGFR 42 ml/min/1.73m², HbA1c 58 mmol/mol, potassium 5.8 mmol/L. What is the most appropriate immediate action?
A. Stop the apixaban and switch to warfarin for better control
B. Add spironolactone 25mg once daily to optimise heart failure management
C. Review the cause of hyperkalaemia and consider stopping metformin temporarily (Correct Answer)
D. Reduce the bisoprolol dose due to chronic kidney disease
E. Increase furosemide to 80mg once daily to improve diuresis
Explanation: ***Review the cause of hyperkalaemia and consider stopping metformin temporarily***
- The patient's **potassium level of 5.8 mmol/L** represents significant **hyperkalaemia** requiring immediate investigation, as this can cause life-threatening **cardiac arrhythmias**.
- With **eGFR 42 ml/min/1.73m²**, **metformin** should be reviewed as NICE guidelines recommend stopping when eGFR falls below 30-45 ml/min/1.73m² due to **lactic acidosis risk**, not hyperkalaemia.
*Stop the apixaban and switch to warfarin for better control*
- **Apixaban** remains safe and effective with **eGFR 42 ml/min/1.73m²**, as dose adjustment is only required when eGFR falls below 30 ml/min/1.73m² (with additional age/weight criteria).
- **Warfarin** offers no advantage over **direct oral anticoagulants (DOACs)** like apixaban and requires more intensive monitoring with greater drug interaction potential.
*Add spironolactone 25mg once daily to optimise heart failure management*
- **Spironolactone** is absolutely contraindicated with **potassium 5.8 mmol/L** as this **mineralocorticoid receptor antagonist** would further increase potassium levels.
- Adding any **potassium-sparing agent** in the presence of existing hyperkalaemia risks precipitating life-threatening **cardiac arrhythmias**.
*Reduce the bisoprolol dose due to chronic kidney disease*
- **Bisoprolol** is primarily **hepatically metabolized** with only 50% renal excretion, so dose adjustment is typically unnecessary until eGFR drops significantly lower.
- The current **2.5mg dose is already low** and appropriate for his **NYHA Class II heart failure** without evidence of bradycardia or hypotension requiring reduction.
*Increase furosemide to 80mg once daily to improve diuresis*
- Increasing **diuretic therapy** without addressing the underlying cause of hyperkalaemia fails to tackle the immediate safety concern of elevated potassium.
- Aggressive diuresis risks **volume depletion** and **pre-renal acute kidney injury**, potentially worsening renal function and exacerbating hyperkalaemia.
Question 40: A 69-year-old woman with heart failure (LVEF 40%), type 2 diabetes, hypertension, and depression takes 11 regular medications. During a structured medication review, she reports a dry cough that has persisted for 6 months. Her medications include ramipril 10mg once daily, bisoprolol 5mg once daily, furosemide 40mg once daily, atorvastatin 80mg once daily, aspirin 75mg once daily, metformin 1g twice daily, gliclazide 80mg twice daily, amlodipine 5mg once daily, sertraline 100mg once daily, lansoprazole 30mg once daily, and calcium/vitamin D supplements. What is the most appropriate initial management?
A. Request a chest X-ray to investigate the persistent cough
B. Switch ramipril to losartan and review symptoms in 2-4 weeks (Correct Answer)
C. Add codeine linctus for symptomatic relief of the cough
D. Refer to respiratory medicine for bronchoscopy
E. Stop the bisoprolol as beta-blockers can cause bronchospasm
Explanation: ***Switch ramipril to losartan and review symptoms in 2-4 weeks***
- A persistent dry cough is a well-known side effect of **ACE inhibitors** like **ramipril**, occurring in up to 15% of patients due to the accumulation of **bradykinin** and substance P.
- Switching to an **Angiotensin II Receptor Blocker (ARB)** like **losartan** provides similar cardiovascular benefits for **heart failure** while eliminating the cough-inducing mechanism without needing to stop crucial medication.
*Request a chest X-ray to investigate the persistent cough*
- While a **chest X-ray** is a reasonable investigation for persistent cough, the most common and easily modifiable cause in this clinical scenario is the **ACE inhibitor**.
- Initiating a medication trial (switching to an **ARB**) is the logical and least invasive initial step before proceeding with further diagnostic imaging.
*Add codeine linctus for symptomatic relief of the cough*
- Adding more medication to a patient already on **polypharmacy** increases the risk of **drug-drug interactions** and side effects (e.g., constipation, sedation).
- **Codeine linctus** only provides symptomatic relief and does not address the underlying cause of the cough, which is the **bradykinin accumulation** from ramipril.
*Refer to respiratory medicine for bronchoscopy*
- **Bronchoscopy** is an invasive and costly procedure that is not indicated as an initial step when a common drug side effect is the most likely cause of the cough.
- Referral to respiratory medicine and bronchoscopy should be considered only if the cough persists after discontinuation of the **ACE inhibitor** or if there are **red flag** symptoms.
*Stop the bisoprolol as beta-blockers can cause bronchospasm*
- While **beta-blockers** can cause **bronchospasm** in susceptible individuals (e.g., asthmatics), they typically do not cause a persistent, non-productive **dry cough**.
- **Bisoprolol** is a vital medication for **Heart Failure with Reduced Ejection Fraction (HFrEF)**, and stopping it without a clear indication could worsen the patient's cardiac condition.
